ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FOMX Foamix Pharmaceuticals Ltd

2.99
0.00 (0.00%)
Apr 25 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 2.80
Ask Price 4.00
News -
Share Name Share Symbol Market Stock Type
Foamix Pharmaceuticals Ltd FOMX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 2.99 19:00:00
Open Price Low Price High Price Close Price Previous Close
2.99 2.99
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0 US$ 2.99 USD

Foamix Pharmaceuticals Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 184.29M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Foamix Pharmaceuticals News

Real-Time news about Foamix Pharmaceuticals Ltd (NASDAQ): 0 recent articles
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No FOMX Message Board. Create One! See More Posts on FOMX Message Board See More Message Board Posts

Historical FOMX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Foamix Pharmaceuticals Description

Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company. It is focused on the development and commercialization of foam based formulations and topical drugs for dermatological therapies mainly acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103, FDX104. The firm also has development and license agreements relating to its technology with various pharmaceutical companies. It has The development and commercialization of foam based formulations segment.

Your Recent History

Delayed Upgrade Clock